• Multiple sclerosis (MS), a chronic, recurrent infl ammatory disease, is characterized by infl ammatory attacks on central nervous system myelin. Patients with MS experience symptoms such as blurred vision, walking and coordination problems, bladder or bowel dysfunction, numbness, and cognitive impairment.
Introduction
• Multiple sclerosis (MS), a chronic, recurrent infl ammatory disease, is characterized by infl ammatory attacks on central nervous system myelin. Patients with MS experience symptoms such as blurred vision, walking and coordination problems, bladder or bowel dysfunction, numbness, and cognitive impairment.
1
• Approximately 85% of patients with MS have relapsing-remitting MS (RRMS), which is characterized by defi ned attacks or relapses that result in worsening of neurological function, with partial to complete recovery between attacks.
2
• Treatment with disease-modifying drugs (DMDs), including interferon beta (IFN ␤) therapies, can reduce relapse rates and delay disability progression and is associated with improved clinical outcomes. [3] [4] [5] • Numerous network meta-analyses (NMAs) have evaluated DMDs in RRMS; however, analyses vary in their inclusion criteria, methodology, and types of statistical syntheses. [6] [7] [8] • A consensus array of inclusion and exclusion criteria, endpoints, and statistical models may identify potential best practices in synthesizing clinical evidence to guide clinical decisions in RRMS.
Objective
• To evaluate different statistical methodologies in an NMA comparing the effectiveness of IFN ␤ therapies across several endpoints in RRMS to determine potential best practices. • Searches were conducted using PubMed, CENTRAL, the • Search terms included: MS, relapsing remitting, relapsing, interferon, peg interferon, RCT, controlled clinical trial, randomized, placebo, drug therapy, randomly, trial, and groups.
Methods
• Inclusion and exclusion criteria for the systematic literature review are presented in Table 1 .
-Data were extracted for patients relapse-free, patients without disability progression, and patients without new magnetic resonance imaging (MRI) activity at study end.
• For all endpoints, data were collected at Year 1, Year 2, and at the longest duration of follow-up, if available.
• An NMA on relevant endpoints was then performed (data on fi le; Table 2 ).
-A random-effects Bayesian model was utilized for the base case analysis.
-Sensitivity analyses investigated results using different analysis frameworks or effects distributions. -Patient withdrawal assumptions:
• Base case analysis assumed patients withdrawing experienced an event.
• Sensitivity analysis did not assume patients withdrawing experienced an event.
Results
• A total of 644 non-duplicate articles were retrieved, of which 14 met the inclusion criteria and reported evaluable data (Figure 2 ).
• Of the 14 articles that reported relevant endpoints, 10 reported freedom from relapse, eight reported freedom from disability progression, and seven reported freedom from MRI progression.
-Of the seven articles reporting MRI activity, three reported active lesions, two reported new/enlarging T2 activity, one reported new/enlarging gadolinium lesions, and one reported new cortical lesions.
• The evidence networks had few connections between nodes, with a maximum of 10 connections for the 'proportion of patients relapse-free' endpoint.
-There were few connections with multiple studies linking nodes, with a maximum of 50% (5/10) of connections having more than one study on the relapse endpoint; there were at most two studies linking any two nodes.
• Due to the small number of studies linking nodes, a random-effects Bayesian model with uninformative priors resulted in wide credible intervals, complicating interpretation of results.
• Uncertainty decreased using a random-effects Bayesian model with an informative prior, as well as with a fi xed-effects Bayesian model.
• The results of the fi xed-effects approach were consistent with those from the random-effects model, albeit with narrower ranges of credible intervals (Figure 3 ).
• Utilizing a Frequentist approach resulted in similar estimates for treatment effects compared with the Bayesian analyses framework, although with slightly less uncertainty (Figure 4 ).
• Infl uence of the patient withdrawal assumption ( Table 2) on model results is shown in Figure 5 .
-For the relapse results, differences in the estimation of one of the treatment effects were observed when comparing base case results with other model results, assuming that censored patients did not experience the event. -For the disability progression results, the estimation of the treatment effects versus all comparators increased when assuming that censored patients did not experience disease progression. -For the MRI activity results, there was no change in the directionality of the results.
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DMD, disease-modifying drug; MRI, magnetic resonance imaging; OR, odds ratio. 
Inclusion criteria Exclusion criteria
At least one of the following therapies as a treatment arm: MRI, magnetic resonance imaging; MS, multiple sclerosis; NMA, network meta-analysis; pegIFN␤1a, pegylated interferon beta-1a; RRMS, relapsing-remitting multiple sclerosis; sc, subcutaneous; scIFN␤1a, subcutaneous interferon beta-1a; scIFN␤1b, subcutaneous interferon beta-1b.
a Freedom from MRI activity was defi ned as the proportion of patients free from newly enhancing gadolinium (Gd) lesions, or from new or enlarged T2 lesions when Gd lesion data were unavailable, or from new active T1 lesions when neither Gd nor T2 lesion data were available.
• Similar estimates for treatment effects were found across all the statistical methodologies examined.
-However, the combination of a Bayesian approach and a random-effects distribution with an informative prior allowed for methodological robustness while yielding interpretable fi ndings.
• Meta-regression analyses are likely to be useful within the RRMS arena, as study-level differences (such as the diagnostic criteria employed and the year of patient enrolment in a study) may lead to signifi cant differences in results observed across trials (data not shown).
Conclusions
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